<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04282486</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL20_0086</org_study_id>
    <nct_id>NCT04282486</nct_id>
  </id_info>
  <brief_title>Medication Exposure in Older Patients With Constitutional Hemorrhagic Disease</brief_title>
  <acronym>M-HEMORRH'AGE</acronym>
  <official_title>Medication Exposure in Older Patients (AGEd &gt; 65 Years) With Constitutional HEMORRHagic Disease (Haemophilia or Willebrand Disease).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The improvements observed in the care of patients with hemophilia or Willebrand disease have
      led to an increase in their life expectancy, which today approaches that of the general
      population. This increase in life expectancy leads in these patients to the development of
      comorbidities related to aging (cardiovascular and neurological diseases, cancers and kidney
      diseases) (e.g &quot;Franchini &amp; Mannuccio&quot;, BJH, 2009). The care of these comorbidities
      represents a new challenge for the medical teams. Toward multiple comorbidities, polypharmacy
      is often associated.

      Many studies about medication exposure and management in older patients were published but no
      study was conducted to explore the medication management of older patients with hemophilia or
      Willebrand disease.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Potentially inappropriate medication (PIM) prevalence using EU-(7) PIM list.</measure>
    <time_frame>At inclusion</time_frame>
    <description>A telephone interview will be conducted with patients in order to collect medication data from medical prescriptions. After collection of data for all patients, the research of PIM was conducted.</description>
  </primary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Hemophilia</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Telephone interview</intervention_name>
    <description>Primary objective: potentially inappropriate medication prevalence
Secondary objective:
Number and type of medication Polypharmacy prevalence Medication regimen complexity using Medication Regimen Complexity Index Anticholinergic and sedative exposure using Drug Burden Index
A telephone interview will be conducted with patients in order to collect medication data from medical prescriptions.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Elderly patients with hemophilia or Willebrand's disease (over 65) will have a telephone
        interview in order to collect medication data from medical prescriptions.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Community-dwelling patients over 65 years with hemophilia (A or B)

          -  Community-dwelling patients over 65 years with Willebrand disease (Type1, 2 and 3,
             rate &lt;30%)

        Exclusion Criteria:

          -  Patients without phone number

          -  Non French speaking patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Teddy NOVAIS, MD</last_name>
    <phone>4 72 43 21 55</phone>
    <phone_ext>+33</phone_ext>
    <email>teddy.novais@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valérie CHAMOUARD</last_name>
    <phone_ext>+33</phone_ext>
    <email>valerie.chamouard@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital des Charpennes, Institut du Vieillissement</name>
      <address>
        <city>Villeurbanne</city>
        <zip>69100</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Teddy NOVAIS, MD</last_name>
      <phone>4 72 43 21 55</phone>
      <phone_ext>+33</phone_ext>
      <email>teddy.novais@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Valérie CHAMOUARD</last_name>
      <phone_ext>+33</phone_ext>
      <email>valerie.chamouard@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Teddy NOVAIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 21, 2020</study_first_submitted>
  <study_first_submitted_qc>February 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2020</study_first_posted>
  <last_update_submitted>February 24, 2020</last_update_submitted>
  <last_update_submitted_qc>February 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Willebrand disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemorrhagic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

